Fulcrum Therapeutics drug pociredir posted early clinical trial results showing signs of treating sickle cell disease with no reports of serious complications. But the biotech is discontinuing this program due to FDA concerns that drugs in this class of medicines raise the risk of cancer.
The post FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug appeared first on MedCity News.
